Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
114.71 USD | -0.54% | -0.94% | +5.22% |
11/09 | Merck: positive results for HPV vaccine | CF |
11/09 | Merck's HPV Vaccine Meets Main Goal in Phase 3 Study in Japanese Males | MT |
Fiscal Period: December | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|---|---|---|---|
Revenues | 4.68TCr | 4.8TCr | 4.87TCr | 5.93TCr | 6.01TCr | |||||
Total Revenues | 4.68TCr | 4.8TCr | 4.87TCr | 5.93TCr | 6.01TCr | |||||
Cost of Goods Sold, Total | 1.32TCr | 1.34TCr | 1.32TCr | 1.72TCr | 1.59TCr | |||||
Gross Profit | 3.37TCr | 3.46TCr | 3.55TCr | 4.21TCr | 4.42TCr | |||||
Selling General & Admin Expenses, Total | 986.3Cr | 937.2Cr | 940.3Cr | 966.9Cr | 988.4Cr | |||||
R&D Expenses | 874.2Cr | 1.03TCr | 1.02TCr | 1.18TCr | 1.83TCr | |||||
Other Operating Expenses, Total | 1.86TCr | 1.97TCr | 1.96TCr | 2.15TCr | 2.82TCr | |||||
Operating Income | 1.51TCr | 1.49TCr | 1.59TCr | 2.06TCr | 1.6TCr | |||||
Interest Expense, Total | -89Cr | -83Cr | -81Cr | -96Cr | -114.6Cr | |||||
Interest And Investment Income | 27Cr | 5.9Cr | 3.6Cr | 31Cr | 36Cr | |||||
Net Interest Expenses | -62Cr | -77Cr | -77Cr | -65Cr | -78Cr | |||||
Income (Loss) On Equity Invest. | - | - | - | - | - | |||||
Currency Exchange Gains (Loss) | -19Cr | -14Cr | -30Cr | -24Cr | -37Cr | |||||
Other Non Operating Income (Expenses) | 11Cr | 13Cr | 26Cr | 52Cr | 42Cr | |||||
EBT, Excl. Unusual Items | 1.44TCr | 1.41TCr | 1.5TCr | 2.02TCr | 1.52TCr | |||||
Restructuring Charges | -93Cr | -88Cr | -87Cr | -67Cr | -93Cr | |||||
Merger & Related Restructuring Charges | -187.1Cr | -475Cr | -170.4Cr | - | -1.14TCr | |||||
Impairment of Goodwill | -16Cr | - | - | - | - | |||||
Gain (Loss) On Sale Of Investments | 17Cr | 133.8Cr | 194Cr | -141.9Cr | 34Cr | |||||
Gain (Loss) On Sale Of Assets | - | - | - | - | - | |||||
Asset Writedown | -17Cr | -9Cr | -28Cr | -160Cr | -78Cr | |||||
In Process R&D Expenses | - | - | - | - | - | |||||
Legal Settlements | - | - | - | - | -57Cr | |||||
Other Unusual Items | 3.9Cr | -92Cr | -26Cr | -7.5Cr | - | |||||
EBT, Incl. Unusual Items | 1.15TCr | 879.1Cr | 1.39TCr | 1.64TCr | 188.9Cr | |||||
Income Tax Expense | 168.7Cr | 170.9Cr | 152.1Cr | 191.8Cr | 151.2Cr | |||||
Earnings From Continuing Operations | 977.7Cr | 708.2Cr | 1.24TCr | 1.45TCr | 38Cr | |||||
Earnings Of Discontinued Operations | - | - | 70Cr | - | - | |||||
Net Income to Company | 977.7Cr | 708.2Cr | 1.31TCr | 1.45TCr | 38Cr | |||||
Minority Interest | 6.6Cr | -1.5Cr | -1.3Cr | -70L | -1.2Cr | |||||
Net Income - (IS) | 984.3Cr | 706.7Cr | 1.3TCr | 1.45TCr | 36Cr | |||||
Net Income to Common Incl Extra Items | 984.3Cr | 706.7Cr | 1.3TCr | 1.45TCr | 36Cr | |||||
Net Income to Common Excl. Extra Items | 984.3Cr | 706.7Cr | 1.23TCr | 1.45TCr | 36Cr | |||||
Per Share Items | ||||||||||
Net EPS - Basic | 3.84 | 2.79 | 5.16 | 5.73 | 0.14 | |||||
Basic EPS - Continuing Operations | 3.84 | 2.79 | 4.88 | 5.73 | 0.14 | |||||
Basic Weighted Average Shares Outstanding | 256.5Cr | 253Cr | 253Cr | 253.2Cr | 253.7Cr | |||||
Net EPS - Diluted | 3.81 | 2.78 | 5.14 | 5.71 | 0.14 | |||||
Diluted EPS - Continuing Operations | 3.81 | 2.78 | 4.86 | 5.71 | 0.14 | |||||
Diluted Weighted Average Shares Outstanding | 258Cr | 254.1Cr | 253.8Cr | 254.2Cr | 254.7Cr | |||||
Normalized Basic EPS | 3.53 | 3.48 | 3.71 | 4.98 | 3.75 | |||||
Normalized Diluted EPS | 3.51 | 3.46 | 3.7 | 4.96 | 3.74 | |||||
Dividend Per Share | 2.2 | 2.44 | 2.6 | 2.76 | 2.92 | |||||
Payout Ratio | 57.86 | 87.94 | 50.66 | 48.3 | 2.04T | |||||
American Depositary Receipts Ratio (ADR) | 0.12 | 0.12 | 0.12 | 0.12 | 0.12 | |||||
Supplemental Items | ||||||||||
EBITDA | 1.85TCr | 1.82TCr | 1.9TCr | 2.44TCr | 1.97TCr | |||||
EBITA | 1.71TCr | 1.68TCr | 1.75TCr | 2.26TCr | 1.8TCr | |||||
EBIT | 1.51TCr | 1.49TCr | 1.59TCr | 2.06TCr | 1.6TCr | |||||
EBITDAR | 1.88TCr | 1.86TCr | 1.93TCr | 2.47TCr | 2TCr | |||||
Effective Tax Rate - (Ratio) | 14.72 | 19.44 | 10.96 | 11.66 | 80.04 | |||||
Current Domestic Taxes | 44Cr | 101.5Cr | 6.1Cr | 232.2Cr | 98Cr | |||||
Current Foreign Taxes | 180.6Cr | 136.2Cr | 127.3Cr | 116.4Cr | 243.5Cr | |||||
Total Current Taxes | 224.3Cr | 237.7Cr | 133.4Cr | 348.6Cr | 341.1Cr | |||||
Deferred Domestic Taxes | -32Cr | -63Cr | 26Cr | -163.9Cr | -166.6Cr | |||||
Deferred Foreign Taxes | -24Cr | -4Cr | -7.7Cr | 7.1Cr | -23Cr | |||||
Total Deferred Taxes | -56Cr | -67Cr | 19Cr | -156.8Cr | -189.9Cr | |||||
Normalized Net Income | 905.79Cr | 879.5Cr | 939.08Cr | 1.26TCr | 951.49Cr | |||||
Non-Cash Pension Expense | -39Cr | -21Cr | 1.7Cr | -10Cr | -40Cr | |||||
Supplemental Operating Expense Items | ||||||||||
Advertising Expense | 210Cr | 200Cr | 200Cr | 220Cr | 230Cr | |||||
Selling and Marketing Expenses | 210Cr | 200Cr | 200Cr | 220Cr | 230Cr | |||||
Research And Development Expense From Footnotes | 987.2Cr | 1.36TCr | 1.22TCr | 1.35TCr | 3.05TCr | |||||
Net Rental Expense, Total | 34Cr | 35Cr | 34Cr | 33Cr | 34Cr | |||||
Imputed Operating Lease Interest Expense | 9.22Cr | 7.57Cr | 6.5Cr | 7.72Cr | 9.11Cr | |||||
Imputed Operating Lease Depreciation | 25Cr | 27Cr | 28Cr | 26Cr | 25Cr | |||||
Stock-Based Comp., Other (Total) | 42Cr | 48Cr | 48Cr | 54Cr | 64Cr | |||||
Total Stock-Based Compensation | 42Cr | 48Cr | 48Cr | 54Cr | 64Cr |